Merck KGaA’s artificial intelligence software for drug discovery is finding its way to Indian start-ups with the company’s process solutions vertical extending a helping hand.
Merck KGaA, Aragen Execs On AI-Led Drug Discovery, Incubator Set-up, US Tariffs And More
Goldman Sachs Investee Seeks Further Funding
Merck’s India head for process solutions and Aragen Bioscience’s CEO talk about an incubator set-up and AI-led drug discovery to enable India’s research ecosystem, US tariffs on China, ADC and GLP-1 development, funding path for Goldman Sachs-investee Aragen and more in this video interview
More from R&D
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from Manufacturing
• By
The company is building on its existing logistics and manufacturing for the radiopharmaceutical drug ITM-11, which delivered positive Phase III data.
• By
CEOs of top Indian firms discuss how policies and geopolitics could shape future manufacturing networks and also the simmering issue of tariffs. US President Donald Trump has just reiterated plans for reciprocal tariffs at a joint session of Congress.
• By
The US stock market broadly declined following increased tariffs on goods from China and new tariffs on goods from Mexico and Canada, but biopharma initially weathered the storm, while pharma faced some headwinds.